What are the treatment indications for chronic hepatitis B infection?

Treatment Indications for Chronic Hepatitis B

All patients with chronic hepatitis B who have HBV DNA >2,000 IU/mL and elevated ALT (>ULN) and/or significant fibrosis should receive antiviral therapy, and all patients with cirrhosis should be treated if HBV DNA is detectable regardless of viral load or ALT level. 1

Core Treatment Criteria

The decision to treat chronic hepatitis B is based on a systematic assessment of viral replication, liver inflammation, and fibrosis stage, as these factors directly predict progression to cirrhosis, hepatocellular carcinoma, and liver-related mortality.

Definite Treatment Indications

HBeAg-Positive Chronic Hepatitis B:

• HBV DNA >20,000 IU/mL (10⁵ copies/mL) AND ALT >2× ULN: Treat immediately 2
• Delay treatment 3-6 months in compensated disease to assess for spontaneous HBeAg seroconversion 2
• Children with ALT >2× ULN for >6 months: Consider treatment 2

HBeAg-Negative Chronic Hepatitis B:

• HBV DNA >2,000 IU/mL (10⁴ copies/mL) AND ALT >ULN: Treat 2, 1
• Lower threshold reflects higher risk of disease progression in this population 3

Cirrhosis (Compensated or Decompensated):

• Any detectable HBV DNA: Treat immediately regardless of ALT level 1
• Prevents hepatic decompensation and reduces HCC risk 4
• Use lamivudine or adefovir for compensated cirrhosis (avoid interferon due to flare risk) 2
• Decompensated cirrhosis requires lamivudine with transplant center coordination; interferon is contraindicated 2

Advanced Fibrosis:

• Metavir F3-F4 or liver stiffness >8 kPa with detectable HBV DNA: Treat regardless of ALT or viral load 1
• Non-invasive markers increasingly guide treatment decisions 4

Expanded Indications (Individualized Assessment)

"Grey Zone" or Indeterminate Phase Patients:

• HBV DNA >2,000 IU/mL with persistently elevated ALT but <2× ULN: Consider liver biopsy 2
• Treat if moderate/severe necroinflammation or significant fibrosis on biopsy 2
• Liver stiffness >9 kPa (normal ALT) or >12 kPa (ALT ≤5× ULN): Treat 4

High-Risk Patients:

• Family history of cirrhosis or HCC with HBV DNA >2,000 IU/mL: Treat 4
• HBeAg-positive patients >30 years old with HBV DNA >20,000 IU/mL: Treat regardless of histology 4
• Immune tolerant phase >40 years old: Consider treatment 5

Persistently Low Viremia:

• HBV DNA <2,000 IU/mL with persistently elevated ALT: Can treat, but exclude other liver diseases first 1

Special Populations Requiring Prophylactic Treatment

Mandatory Prophylaxis:

• Immunosuppression/chemotherapy: Prevents HBV reactivation (20-50% risk without prophylaxis) 2
• Liver transplantation: Prevents recurrence 4
• Pregnancy (third trimester) with high viremia: Prevents vertical transmission 4

Other Indications:

• Co-infections (HIV, HCV, HDV) 4
• Extrahepatic manifestations 4
• Severe acute hepatitis B 4
• Healthcare workers with viremia 4

Do NOT Treat

Inactive HBsAg Carrier State:

• HBsAg-positive, HBeAg-negative, HBV DNA <2,000 IU/mL, persistently normal ALT
• No treatment indicated 2
• Monitor periodically for reactivation 2

Immune Tolerant Phase (Standard Criteria):

• HBeAg-positive, very high HBV DNA, persistently normal ALT, minimal histologic changes
• Do not treat unless >40 years old or evidence of disease progression 2, 5

Common Pitfalls to Avoid

1. Missing cirrhosis patients: Any detectable HBV DNA in cirrhosis warrants treatment—do not wait for ALT elevation
2. Overlooking "grey zone" patients: Use liver biopsy or non-invasive fibrosis assessment when ALT is minimally elevated
3. Forgetting prophylaxis: Screen all patients before immunosuppression/chemotherapy
4. Interferon in decompensated cirrhosis: Absolutely contraindicated due to flare risk 2
5. Under-recognizing low viral load risk: Patients with HBV DNA <2,000 IU/mL and elevated ALT may have other liver diseases—investigate thoroughly 1

Treatment Selection Framework

The 2025 EASL guidelines 1 and recent evidence 5 support broader treatment access, particularly with safer nucleos(t)ide analogues now available as generics. First-line agents are pegylated interferon, entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide 1. The choice depends on patient age, cirrhosis status, pregnancy plans, and treatment goals (finite vs. indefinite therapy).

The evidence strongly supports treating patients with active viral replication and liver inflammation or fibrosis, as antiviral therapy demonstrably prevents cirrhosis, hepatocellular carcinoma, and liver-related death 1, 4.